adenomatous_polyposis_coli:n
adenomatous_polyposis_coli:y
adjchemo:no
adjchemo:yes
age:0
age:1
age:100
age:12
age:13
age:14
age:168 days since seeding of singe-cell
age:17
age:18
age:19
age:2
age:20
age:21
age:22
age:23
age:24
age:24 h
age:25
age:26
age:27
age:28
age:29
age:3
age:30
age:30-34
age:31
age:32
age:32.45448323066393
age:33
age:33.11944444444445
age:33.26301369863014
age:34
age:34.97260273972603
age:35
age:36
age:36.94722222222222
age:37
age:37y
age:38
age:38.55068493150685
age:38y
age:39
age:39.43052703627652
age:39y
age:40
age:40.513888888888886
age:41
age:42
age:42y
age:43
age:44
age:44-year-old
age:44-years-old
age:44.7
age:45
age:45y
age:46
age:46 year
age:46.3013698630137
age:46y
age:47
age:47.43326488706366
age:47.778082191780825
age:47y
age:48
age:48.1
age:48.35044490075291
age:48y
age:49
age:49 years
age:49y
age:50
age:50 years
age:50.08333333
age:50.1
age:50.41666667
age:50.83333333
age:50y
age:51
age:51 years
age:51-year-old
age:51y
age:52
age:52 years
age:52.236111111111114
age:52.91666667
age:53
age:53 years
age:53y
age:54
age:54 years
age:54y
age:55
age:55 years
age:55-59
age:55.1
age:55.12602739726027
age:55.5
age:55y
age:56
age:56 years
age:56 years old
age:56.08333333
age:56y
age:57
age:57 years
age:57.352777777777774
age:57y
age:58
age:58y
age:59
age:59 years
age:59 years old
age:59.25
age:59y
age:60
age:60 years
age:60y
age:61
age:61 years
age:61.08333333
age:61.5
age:61.92602739726028
age:62
age:62 years
age:62.1
age:62.2
age:62.3
age:62.5
age:62y
age:63
age:63 years
age:63.08333333
age:63.5
age:63y
age:64
age:64 years
age:64.30958904109589
age:64.91388888888889
age:64y
age:65
age:65 years
age:65-69
age:65.1
age:65.34246575342466
age:65.5
age:65.7
age:65y
age:66
age:66 years
age:66y
age:67
age:67 years
age:67.26849315068493
age:67.54520547945205
age:67y
age:68
age:68 +/- 12
age:68 years
age:68.41666667
age:68.870636550308
age:68y
age:69
age:69 years
age:69.1
age:69.58333333
age:69y
age:70
age:70 years
age:70 years old
age:70.2
age:70y
age:71
age:71 years
age:71.5400410677618
age:71y
age:72
age:72 years
age:72.35342465753425
age:72y
age:73
age:73 years
age:73 years old
age:73 years replicate 1
age:73 years replicate 2
age:73 years replicate 3
age:73y
age:74
age:74 years
age:74.1
age:74y
age:75
age:75 years
age:75.91666667
age:75y
age:76
age:76 years
age:76y
age:77
age:77.25
age:77.7388888888889
age:78
age:78 days since seeding of singe-cell
age:78y
age:79
age:79y
age:80
age:80 years old
age:80.75
age:80.83333333
age:80y
age:81
age:82
age:82.01095890410959
age:83
age:83.41666667
age:83y
age:84
age:85
age:85y
age:86
age:86y
age:87
age:88
age:88.75
age:88y
age:89
age:90
age:91
age:92
age:94
age:95
age:96
age:adult
age:fetus
age:generation 20-25
age:low pass
age:missing: control sample
age:mixed sample
agent:dmso
agent:f. nucleatum
agent:it1208
agent:oxa
agent:oxa+vola
agent:vola
ajcc:#n/a
ajcc:0
ajcc:1
ajcc:2
ajcc:3
ajcc:4
ajcc:adenocarcinoma
ajcc:adenoma
ajcc:adenomatous colon polyp
ajcc:adult
ajcc:advanced adenoma
ajcc:ajcc: iia
ajcc:ajcc: iib
ajcc:ajcc: iv
ajcc:breast cancer
ajcc:bud cell
ajcc:c180
ajcc:c182
ajcc:c183
ajcc:c184
ajcc:c185
ajcc:c187
ajcc:c189
ajcc:c19
ajcc:c199
ajcc:c20
ajcc:cancer
ajcc:carcinoma; colorectal
ajcc:cd
ajcc:cell
ajcc:colon
ajcc:colon adenocarcinoma
ajcc:colon cancer
ajcc:colon carcinoma
ajcc:colon sessile serrated adenoma/polyp
ajcc:colorectal
ajcc:colorectal adenocarcinoma
ajcc:colorectal adenoma
ajcc:colorectal cancer
ajcc:colorectal cancer (adenocarcinoma)
ajcc:colorectal cancer (crc)
ajcc:colorectal cancer patient
ajcc:colorectal cancerliver metastasis
ajcc:colorectal cancerlymph node metastasis
ajcc:colorectal carcinoma
ajcc:colorectal neoplasms
ajcc:colorectal tumor organoids
ajcc:colorectal_cancer
ajcc:complete response
ajcc:control
ajcc:copd
ajcc:crc
ajcc:crclm
ajcc:crohn's
ajcc:deceased
ajcc:disease free
ajcc:dukes' type bcolorectal adenocarcinoma
ajcc:dukes' type ccolorectal adenocarcinoma
ajcc:early-onset colorectal cancer
ajcc:gastrointestinal adenoma
ajcc:gastrointestinal system cancer
ajcc:healthy
ajcc:high grade dysplasia
ajcc:hnpcc family
ajcc:human colorectal cancer
ajcc:i
ajcc:ii
ajcc:iia
ajcc:iib
ajcc:iic
ajcc:iii
ajcc:iiia
ajcc:iiib
ajcc:iiic
ajcc:intestinal benign neoplasm
ajcc:iv
ajcc:iva
ajcc:ivb
ajcc:late
ajcc:late-onset colorectal cancer
ajcc:liver metastasis colorectal cancer
ajcc:low grade dysplasia
ajcc:lung cancer
ajcc:m0
ajcc:main cell
ajcc:mcrc
ajcc:metastasis
ajcc:metastatic colorectal cancer
ajcc:mucosa
ajcc:n0
ajcc:n1
ajcc:n2
ajcc:negative for dysplasia
ajcc:non-advanced adenoma
ajcc:non-metastatic colorectal cancer (crc)
ajcc:normal
ajcc:other
ajcc:ovarian cancer
ajcc:papillary thyroid cancer
ajcc:patient-derived organoids - cms3
ajcc:peptic ulcer
ajcc:polyp
ajcc:primary colorectal cancer cell line
ajcc:primary colorectal tumor resection
ajcc:primary neoplasm
ajcc:primary sclerosing cholangitis/ulcerative colitis
ajcc:prostate cancer
ajcc:pt1n0m0
ajcc:pt2n0m0
ajcc:pt2n1m0
ajcc:pt2n2m0
ajcc:pt3n0m0
ajcc:pt3n1m0
ajcc:pt3n1m1
ajcc:pt3n2m0
ajcc:pt4n0m0
ajcc:pt4n1m0
ajcc:pt4n2m0
ajcc:pt4n2m1
ajcc:ptis
ajcc:rectal cancer
ajcc:rheumatoid arthritis
ajcc:signet ring cell carcinoma
ajcc:stage 0
ajcc:stage 1
ajcc:stage 2
ajcc:stage 3
ajcc:stage 4
ajcc:stage ii
ajcc:stage iii
ajcc:stage iv
ajcc:stageⅱ
ajcc:stageⅲ
ajcc:stageⅳ
ajcc:stomach cancer
ajcc:t1n0m0
ajcc:t2n0
ajcc:t2n0m0
ajcc:t2n0m1
ajcc:t2n1
ajcc:t2n1m1
ajcc:t3 n0 m0
ajcc:t3 n1 m0
ajcc:t3 n2 m0
ajcc:t3an1
ajcc:t3an1b
ajcc:t3an2a
ajcc:t3bn2a
ajcc:t3bn2b
ajcc:t3cn2b
ajcc:t3n0m0
ajcc:t3n0m1
ajcc:t3n1m0
ajcc:t3n1m0 (ⅲb)
ajcc:t3n1m1
ajcc:t3n2m0
ajcc:t3n2m1
ajcc:t4an0m0; iib
ajcc:t4an1m1
ajcc:t4an2b
ajcc:t4an2m0
ajcc:t4bn2a
ajcc:t4n01m0; iii
ajcc:t4n0m0
ajcc:t4n1bm0 (ⅲb)
ajcc:t4n1m0
ajcc:t4n1m1
ajcc:t4n1mo
ajcc:t4n2m0
ajcc:t4n2m1
ajcc:t4nxm1
ajcc:tisn0m0
ajcc:tnm0
ajcc:tnm1
ajcc:tnm2
ajcc:tnm3
ajcc:tnm4
ajcc:treatment
ajcc:tumor
ajcc:tumour
ajcc:uc
ajcc:ulcerative colitis
ajcc:unaffected
ajcc:urinary cancer
ajcc:ypt2n0m0
ajcc:ypt3n0m0
ajcc:ypt3n0m1
ajcc:ypt3n1m0
ajcc:ypt3n2m0
ajcc:ypt3n2m1
ajcc:ypt4n0m1
ajcc:ⅳa
ambient_o2_concentration:0.50%
apical_nod_or_root_nodes_neoplasm_metastasis_0_no_1_yes:0
apical_nod_or_root_nodes_neoplasm_metastasis_0_no_1_yes:1
biopsy_site:blood
biopsy_site:colon
biopsy_site:colon/rectum
biopsy_site:colon: rectosigmoid
biopsy_site:colon: splenic flexure
biopsy_site:healthy adjacent tissue
biopsy_site:large_intestine
biopsy_site:left flank
biopsy_site:liver
biopsy_site:lung
biopsy_site:mixed neoplasm and adjacent normal tissue
biopsy_site:neoplasm
biopsy_site:normal tissue
biopsy_site:normal tissue adjacent to neoplasm
biopsy_site:normal tissue adjacent to tumour
biopsy_site:rectum: upper
biopsy_site:right flank
biopsy_site:right side of tumor o
biopsy_site:small_intestine
biopsy_site:tumor tissue
body_mass_index:0
body_mass_index:15
body_mass_index:17
body_mass_index:19
body_mass_index:20
body_mass_index:21
body_mass_index:22
body_mass_index:23
body_mass_index:24
body_mass_index:25
body_mass_index:26
body_mass_index:27
body_mass_index:28
body_mass_index:29
body_mass_index:30
body_mass_index:31
body_mass_index:32
body_mass_index:33
body_mass_index:34
body_mass_index:36
body_mass_index:37
body_mass_index:40
body_product:stool
braf_alleles:braf v600e
braf_alleles:braf wt
braf_status:p.v600e
braf_status:wt
brafi_resistance:not resistant to braf inhibitors
brafi_resistance:resistant to braf inhibitors
ca199_at_recurrence:x
cd38_level:cd38_hi
cd38_level:cd38_low
cd44v6_status:negative
cd44v6_status:positive
cd4:2140
cd8:1377
cd8:1940
cd8:363
cd8:968
cea_at_recurrence:x
cetuximab_resistance:nd
cetuximab_resistance:resistant
cetuximab_resistance:sensitive
cetuximab_sensitivity_and_specificity:resisitant
cetuximab_sensitivity_and_specificity:sensitive
clinical_history:moderately differentiatedt3 n1
clinical_information:desmoplastic histopathological growth pattern
clinical_information:no previous treatment; no tumor regression
clinical_information:oxaliplatin and capecitabine combined chemotherapy
clinical_information:replacement histopathological growth pattern
clinical_information:short course radiotherapy; tumor regression 3
clinical_response:progressive disease (pd)
cohort:singapore
colorectal_neoplasms_stadium:i
colorectal_neoplasms_stadium:ii
colorectal_neoplasms_stadium:iiia
colorectal_neoplasms_stadium:iiib
condition:2d monolayer
condition:3d bioprint
condition:normal
condition:polyp
condition:tumoral
condition_of_the_patients_at_last_follow_up_1_alive_no_disease_:1
condition_of_the_patients_at_last_follow_up_1_alive_no_disease_:2
condition_of_the_patients_at_last_follow_up_1_alive_no_disease_:3
condition_of_the_patients_at_last_follow_up_1_alive_no_disease_:4
control_therapeutics:cfse d1
country:chinese in eastern china
country:czech republic
country:france
country:germany
country:han chinese
country:hong kong
country:italy
country:nigeria
country:united kingdom
country:usa
crc_grade:2
crc_grade:ajcc g2: moderately differentiated
crc_grade:good
crc_grade:high
crc_grade:intermediate
crc_grade:low
crc_grade:minimal
crc_grade:moderate
crc_grade:mucineus
crc_grade:mucineus/scd
crc_grade:near total
crc_grade:poor
crc_grade:signet cell
crc_grade:stage i
crc_grade:stage iia
crc_grade:stage iiia
crc_grade:stage iiib
crc_grade:stage iv
crc_grade:stage_i
crc_grade:stage_ii
crc_grade:stage_iii
crc_grade:stage_iv
crc_grade:total
crc_type:mssbraf-v600e, apc-mutant, colorectal cancer
crispr_therapy:+dox
crispr_therapy:10kpa substrate stiffness
crispr_therapy:16 hours doxycyclin
crispr_therapy:18 hours dmso
crispr_therapy:1874
crispr_therapy:1kpa substrate stiffness
crispr_therapy:1um afuresertib
crispr_therapy:20μm dha
crispr_therapy:3.4gpa substrate stiffness
crispr_therapy:3tc
crispr_therapy:4-tert-octylphenol (op)
crispr_therapy:40kpa substrate stiffness
crispr_therapy:48 hours doxycyclin
crispr_therapy:5 d cetuximab
crispr_therapy:5-aza-2-deoxycytidine
crispr_therapy:5-aza-cdr
crispr_therapy:5-fluorouracil
crispr_therapy:5-fluorouracil + targeted drugs
crispr_therapy:5-fluorouracil for 12 hours followed by 3-mb-pp1 for 4 hours
crispr_therapy:5-fluorouracil for 12 hours followed by dmso for 4 hours
crispr_therapy:5-fu
crispr_therapy:5-fu/lv
crispr_therapy:5fu 10 um 24h
crispr_therapy:5fu 10 um 24h + irradiation (dl50)
crispr_therapy:6853
crispr_therapy:8679
crispr_therapy:9-cis ra
crispr_therapy:9-ing-41
crispr_therapy:_naive
crispr_therapy:ago2 knockdown
crispr_therapy:ago2 wildtype
crispr_therapy:amino acid deprivation
crispr_therapy:anti-pd1 (pembrolizumab)
crispr_therapy:asa_hypoxia
crispr_therapy:bevacizumab
crispr_therapy:bevacizumab/cetuximab
crispr_therapy:bisphenol a (bpa)
crispr_therapy:bort_3h
crispr_therapy:c
crispr_therapy:cabozantinib
crispr_therapy:cana+il1b
crispr_therapy:cetuximab
crispr_therapy:cetuximab secondary resistant tumors following cetuximab
crispr_therapy:chemo-resistance
crispr_therapy:chemo-resistant
crispr_therapy:chemo-sensitive
crispr_therapy:cobimetinib
crispr_therapy:complete medium
crispr_therapy:complete medium for 6 hrs
crispr_therapy:control
crispr_therapy:control dmso
crispr_therapy:control medium
crispr_therapy:control medium (10%fbs+4.5g/l glucose)
crispr_therapy:control samples
crispr_therapy:cpt-11
crispr_therapy:ctrl_0h
crispr_therapy:cystine-restriction medium
crispr_therapy:cystine-restriction medium for 6 hrs
crispr_therapy:dac-treated
crispr_therapy:dasatinib
crispr_therapy:decitabine treated
crispr_therapy:denatured control
crispr_therapy:dihydroartemisinin 20ug/ml 4 h
crispr_therapy:dimethyl sulfoxide 1μm
crispr_therapy:dmso
crispr_therapy:dmso for 12 hours followed by 3-mb-pp1 for 4 hours
crispr_therapy:dmso for 12 hours followed by dmso for 4 hours
crispr_therapy:dmso treated
crispr_therapy:dmso_hypoxia
crispr_therapy:dox
crispr_therapy:doxorubicin at a final concentration of 300 nm for 16 hours
crispr_therapy:doxycycline
crispr_therapy:doxycycline for 48h
crispr_therapy:doxycycline for 96h
crispr_therapy:doxycycline treating 48 h
crispr_therapy:dse+tgfb
crispr_therapy:e7107
crispr_therapy:erbitux+folfirioxaliplatin
crispr_therapy:etoh
crispr_therapy:ex-vivo perfused tumors treated with higg1 dx17
crispr_therapy:ex-vivo perfused tumors treated with higg1 lalapg
crispr_therapy:f. nucleatum cocultured
crispr_therapy:fasting medium (1%fbs+1g/l glucose)
crispr_therapy:folfiri
crispr_therapy:folfiri+avastin
crispr_therapy:folfiri/bevacizumab
crispr_therapy:folfox
crispr_therapy:folfox+vectibix
crispr_therapy:folfox+vectibix neodajuvantlyfufa+avastin
crispr_therapy:folfox/bevacizumab
crispr_therapy:folfoxfolfiri
crispr_therapy:folfoxfolfiri/bevacizumab
crispr_therapy:folfoxfufa
crispr_therapy:folfoxgemcitabin
crispr_therapy:fraction of radiotherapy:60gy/14f
crispr_therapy:fraction of radiotherapy:60gy/16f
crispr_therapy:fraction of radiotherapy:60gy/18f
crispr_therapy:fufa
crispr_therapy:fufa+avastin
crispr_therapy:g2_0h
crispr_therapy:gevo+il1b
crispr_therapy:hcq-evolved
crispr_therapy:hct116 shatgl treated with doxycycline (2ug/ml) for 48h
crispr_therapy:hct116-nc
crispr_therapy:hct116-simv
crispr_therapy:hexabromocyclododecane (hbcd)
crispr_therapy:hr488b 1μm
crispr_therapy:htyr
crispr_therapy:hx531
crispr_therapy:icrt3
crispr_therapy:igg2+tgfb1
crispr_therapy:infected with lenti-cxcr7
crispr_therapy:infected with vector control
crispr_therapy:input control from hypoxia
crispr_therapy:isotype+il1b
crispr_therapy:isotype+tgfb
crispr_therapy:itraconazole
crispr_therapy:jq1 (500 nm, 24 hr)
crispr_therapy:jq1 1µm
crispr_therapy:kr12 (500 nm)
crispr_therapy:medium control
crispr_therapy:mek inhibitor
crispr_therapy:mg132+a-aman_3h
crispr_therapy:mg132_3h
crispr_therapy:minus-reagent
crispr_therapy:ml00754792
crispr_therapy:mock
crispr_therapy:mock-treated
crispr_therapy:morindone
crispr_therapy:mpt-0b014
crispr_therapy:ms-275
crispr_therapy:naïve
crispr_therapy:negative control
crispr_therapy:neoadjuvant chemotherapy
crispr_therapy:nis+tgfb
crispr_therapy:nis793+tgfb1
crispr_therapy:nivo+spdl-1 for 24h
crispr_therapy:nivo+spdl-1 for 6h
crispr_therapy:nivo+spdl-2 for 24h
crispr_therapy:nivo+spdl-2 for 6h
crispr_therapy:nivolumab (nivo) for 24h
crispr_therapy:nivolumab (nivo) for 6h
crispr_therapy:no
crispr_therapy:no dox
crispr_therapy:no neoadjuvant chemotherapy
crispr_therapy:no vit a
crispr_therapy:non dac-treated
crispr_therapy:non-treated control
crispr_therapy:none (=untreated = ut = 0h)
crispr_therapy:normal
crispr_therapy:np
crispr_therapy:nrx194204
crispr_therapy:olaparib
crispr_therapy:opwps treatment
crispr_therapy:overexpressed gap43
crispr_therapy:oxaliplatin
crispr_therapy:oxaliplatinfolfox+vectibix folfiri
crispr_therapy:palbociclib
crispr_therapy:panitumumab 230ug/ml
crispr_therapy:pbmc at cycle 1
crispr_therapy:pbmc at cycle 2
crispr_therapy:pbmc at time of surgery
crispr_therapy:pbs
crispr_therapy:ph 6.6
crispr_therapy:ph 6.9
crispr_therapy:ph 7.4
crispr_therapy:plus-reagent
crispr_therapy:poly(i:c)
crispr_therapy:post-
crispr_therapy:post-tx non-pd
crispr_therapy:post-tx pd
crispr_therapy:pre-treatment
crispr_therapy:pre-tx
crispr_therapy:pum1 antibody pull down
crispr_therapy:r568
crispr_therapy:radiotherapy
crispr_therapy:rnf43_g659 mutations
crispr_therapy:saline
crispr_therapy:scramble sirna transfected
crispr_therapy:scrambled shrna control (shrna/control) using a lentiviral shrna technique
crispr_therapy:selumetinib
crispr_therapy:shctrl dmso
crispr_therapy:shctrl vxn
crispr_therapy:shfoxa2
crispr_therapy:shmt2 knockdown
crispr_therapy:shnc
crispr_therapy:shrna-mediated silencing of apc
crispr_therapy:shslc6a3 dmso
crispr_therapy:sictl
crispr_therapy:sictnnb1
crispr_therapy:sineg
crispr_therapy:solubile-pdl-1 (spdl-1) for 24h
crispr_therapy:solubile-pdl-1 (spdl-1) for 6h
crispr_therapy:solvent
crispr_therapy:sorafenib
crispr_therapy:sp2509
crispr_therapy:surgical
crispr_therapy:surgical/chemotherapy
crispr_therapy:tgfb1+dse
crispr_therapy:tnfalpha
crispr_therapy:trametinib
crispr_therapy:trametinib + jq1
crispr_therapy:trametinib 30nm
crispr_therapy:transcatheter arterial infusion chemotherapy one week before surgical resection
crispr_therapy:transfected with mettl14 overexpression plasmids
crispr_therapy:transfected with negative control plasmids
crispr_therapy:treated
crispr_therapy:treated with il6/8
crispr_therapy:treatment-naïve
crispr_therapy:trg4-5
crispr_therapy:tumor at time of surgery
crispr_therapy:tyw2 ko
crispr_therapy:unculturedfacs sorted cholangiocytes
crispr_therapy:untreated
crispr_therapy:uracil 10 um 24h
crispr_therapy:vehicle
crispr_therapy:vehicle ctr
crispr_therapy:with dmem medium cultured in 37 c5%co2.
crispr_therapy:without treatment
diagnosis:cancer
diagnosis:colon cancer
diagnosis:colorectal adenocarcinoma tissue
diagnosis:colorectal cancer
diagnosis:early onset colorectal cancer
diagnosis:large adenoma
diagnosis:metastasis
diagnosis:non-small cell lung cancer (nsclc)
diagnosis:normal
diagnosis:normalmetastasis of colorectal cancer
diagnosis:rectal cancer
diagnosis:small adenoma
diagnosis:surrounding healthy tissue
disease_staging:pt3 n2a m0
disease_staging:pt4a n2a m0
disease_status:cancer
dosage_dose:1.8
dosage_dose:500 nm
dose_level:0.1 mg/kg
dose_level:0.1mg/kg
dose_level:1.0 mg/kg
dose_pharmaceutical_preparations:1.8
dose_pharmaceutical_preparations:500 nm
dose_pharmaceutical_preparations:fluorouracil (5-fu)
doxycycline_induction:+
drinking:no
drinking:yes
drug:adenine
drug:adenosine
drug:adenosine triphosphate
drug:aflibercept
drug:aliskiren
drug:amphotericin b
drug:artemisinin
drug:aspirin
drug:atezolizumab
drug:avelumab
drug:azacitidine
drug:bevacizumab
drug:bortezomib
drug:cabozantinib
drug:canakinumab
drug:capecitabine
drug:cetuximab
drug:chloroquine
drug:collagenase
drug:crizotinib
drug:dabrafenib
drug:dasatinib
drug:decitabine
drug:denosumab
drug:deoxycytidine
drug:dihydroartemisinin
drug:docetaxel
drug:dopamine
drug:doxorubicin
drug:doxycycline
drug:durvalumab
drug:epidermal growth factor
drug:erdafitinib
drug:erlotinib
drug:estrogen
drug:ethanol
drug:everolimus
drug:fexofenadine
drug:fluorouracil
drug:gentamicin
drug:glutathione
drug:glycine
drug:hegf
drug:hydroxychloroquine
drug:hydroxyurea
drug:imatinib
drug:infigratinib
drug:infliximab
drug:irinotecan
drug:iron
drug:itraconazole
drug:lenvatinib
drug:magnesium
drug:metformin
drug:metronidazole
drug:minaprine
drug:nicotinamide
drug:nitric oxide
drug:nivolumab
drug:olaparib
drug:oxaliplatin
drug:palbociclib
drug:panitumumab
drug:pembrolizumab
drug:penicillin
drug:perazine
drug:piperazine
drug:regorafenib
drug:romidepsin
drug:simvastatin
drug:sodium bicarbonate
drug:sorafenib
drug:streptomycin
drug:succinic acid
drug:temozolomide
drug:thalidomide
drug:trametinib
drug:trastuzumab
drug:tremelimumab
drug:trypan blue
drug:uridine
drug:vitamin a
duration_of_hypoxia:16 hours
duration_of_therapy:1 hrs
duration_of_therapy:24 hrs
duration_of_therapy:6 hrs
duration_of_therapy:7 months
duration_of_therapy:72 hrs
duration_of_therapy:8 weeks
ethinicity:africa
ethinicity:american indian or alaska native
ethinicity:asia
ethinicity:asian
ethinicity:black or african american
ethinicity:cauc
ethinicity:caucasian
ethinicity:crc-tcr_01
ethinicity:crc_tcr02
ethinicity:crc_tcr03
ethinicity:crc_tcr04
ethinicity:crc_tcr05
ethinicity:crc_tcr07_reseq
ethinicity:crc_tcr08
ethinicity:crc_tcr09
ethinicity:crc_tcr10
ethinicity:crc_tcr11
ethinicity:crc_tcr_06
ethinicity:east asian
ethinicity:ethnic
ethinicity:han
ethinicity:japanese
ethinicity:korean
ethinicity:latin
ethinicity:mestizo
ethinicity:mongoloid
ethinicity:more then one race
ethinicity:native hawaiian or other pacific islander
ethinicity:not hispanic or latino
ethinicity:other
ethinicity:other-unknown
ethinicity:taiwanese
ethinicity:unkn
ethinicity:white
ethinicity:white or caucasian
ethinicity:yoruba
fluorouracil_sensitivity_and_specificity:resistant
fluorouracil_sensitivity_and_specificity:sensitive
follow_up:negative
follow_up:positive
foxp3:0
gender_identity:female
gender_identity:male
gender_identity:missing: control sample
gender_identity:not determined
gender_identity:pooled male and female
genes_mutated:mlh1
genes_mutated:msh2
genes_mutated:msh6
genes_mutated:pms2
genetic_modification:control
genetic_modification:riz2 overexpression
genotype_variation:apc-/-krasg12d tp53-/-
genotype_variation:apc-/-krasg12d tp53-/- smad4-/-
genotype_variation:apc-/-krasg12d, tp53-/-
genotype_variation:apc-/-krasg12d, tp53-/-, smad4-/-
genotype_variation:bex2 knocked out
genotype_variation:braf v600e
genotype_variation:braf wildtype
genotype_variation:braf wt
genotype_variation:brafv600e
genotype_variation:control
genotype_variation:ern1 ko
genotype_variation:ern1/cbfb double ko
genotype_variation:ern1/runx2 double ko
genotype_variation:hoxb8 knock-down
genotype_variation:luciferase sirna
genotype_variation:si-control transcript
genotype_variation:si-ythdf3
genotype_variation:staufen1 sirna
genotype_variation:wild type
health_state:cancer
health_state:colorectal cancer
health_state:crc
health_state:disease
health_state:healthy
health_state:n
health_state:normal
health_state:t
health_state:tumor
height:1.45
height:1.5
height:1.52
height:1.53
height:1.55
height:1.56
height:1.57
height:1.58
height:1.59
height:1.6
height:1.62
height:1.65
height:1.66
height:1.68
height:1.69
height:1.7
height:1.71
height:1.72
height:1.73
height:1.74
height:1.75
height:1.78
histological_type_1_adeno_ca_2_mucinous_ca_mucins_50_3_signet_c:1
histology:adenocarcinoma
histology:colon adenocarcinoma
histotype:adenoca g2
histotype:adenoca g3
hnf4alpha_protein_isoforms:isoform 1
hnf4alpha_protein_isoforms:isoform 10
hnf4alpha_protein_isoforms:isoform 11
hnf4alpha_protein_isoforms:isoform 12
hnf4alpha_protein_isoforms:isoform 2
hnf4alpha_protein_isoforms:isoform 3
hnf4alpha_protein_isoforms:isoform 4
hnf4alpha_protein_isoforms:isoform 5
hnf4alpha_protein_isoforms:isoform 6
hnf4alpha_protein_isoforms:isoform 7
hnf4alpha_protein_isoforms:isoform 8
hnf4alpha_protein_isoforms:isoform 9
imatinib_mesylate:post-imatinib
imatinib_mesylate:pre-
immunophenotype:cd161- cd4
immunophenotype:cd161hi cd56+ cd4
immunophenotype:cd161hi cd56- cd4
immunophenotype:cd161int cd4
immunophenotype:cd3-positive
infections:with tko v.3 library
inflammation_status:inflamed
inflammation_status:uninflamed
is_neoplasms:no
is_neoplasms:yes
kras:mutated (g12d)
lnm_status:lnm-negative
lnm_status:lnm-positive
localization:lc
localization:left
localization:other
localization:rc
localization:rectum
localization:right
localization:sigma
location_in_colon:left
location_in_colon:right
location_in_colon:transverse
location_of_metachronous_neoplasms_1_cecum_2_a_colon_3_hepatic_:x
location_primary_neoplasms:ascending colon
location_primary_neoplasms:coecum
location_primary_neoplasms:lienal flexure
location_primary_neoplasms:rectum
location_primary_neoplasms:sigmoid
lvi:absent
lvi:present
m:0
m:1
m:1a
m:mx
m_0_9:0
mmr:msi
msi:no
msi:yes
msi_status:msi
msi_status:mss
msi_status:nd
mutation:apc-/-krasg12d tp53-/-
mutation:apc-/-krasg12d tp53-/- smad4-/-
mutation:apc-/-krasg12d, tp53-/-
mutation:apc-/-krasg12d, tp53-/-, smad4-/-
n:0
n:1
n:1b
n:2a
n:2b
n:n2
n_1_3:0
n_1_3:1
n_1_3:2
n_staging:n0
n_staging:n1
nancy_score:0
nancy_score:1
nancy_score:2
nancy_score:3
nancy_score:4
neoplasm_staging:pt1 n0
neoplasm_staging:pt2 n0
neoplasm_staging:pt3 n0
neoplasm_staging:pt3 n1b
neoplasm_staging:pt3 n1c
neoplasm_staging:t3 n0
neoplasms_localization:ascending colon
neoplasms_localization:cecum
neoplasms_localization:descending colon
neoplasms_localization:hepatic flexure
neoplasms_localization:rectosigmoid junction
neoplasms_localization:rectum
neoplasms_localization:sigmoid colon
neoplasms_localization:splenic flexure
neoplasms_location:ascending
neoplasms_location:ascending colon
neoplasms_location:cecum
neoplasms_location:colon
neoplasms_location:descending colon
neoplasms_location:hepatic flexure colon
neoplasms_location:rectosigmoid junction rectum
neoplasms_location:rectum
neoplasms_location:sigmoid
neoplasms_location:sigmoid colon
neoplasms_location:splenic flexure colon
neoplasms_location:transverse colon
organ:bronchus metastasis of colorectal cancer
organ:skin metastasis of colorectal cancer
other_pathological_parameters_1_blood_vascular_invasion_2_lymph:0e
other_pathological_parameters_1_blood_vascular_invasion_2_lymph:6
other_pathological_parameters_1_blood_vascular_invasion_2_lymph:6d
other_pathological_parameters_1_blood_vascular_invasion_2_lymph:6e
outcome:favorable; no evidence of disease recurrence within 5 yrs from chemotherapy
outcome:unfavorable; evidence of disease recurrence within 3 yrs from chemotherapy
polyps:no
polyps:yes
puromycin_resistance:resistant
regimen:2hr then heatshock for 0.5hrthe recover 1hr all under drug treatment
regimen:2hr then heatshock for 0.5hrthe recover 1hr, all under drug treatment
smoking:former/current
smoking:never
smoking:no
smoking:yes
systemic_recurrence:no
systemic_recurrence:yes
t:2
t:3
t:4
t:4a
t:t3
t_extent:t1
t_extent:t2
t_extent:t3
t_extent:t4
t_is_4:3
t_is_4:4
tcra:htai-m01
tcra:htai-m02
tcra:htai-m03
tcra:htai-m04
tcra:htai-m05
tcra:htai-m06
tcra:htai-m08
tcra:htai-m09
tcra:htai-m10
tcra:htai-m11
tcrb:htbi-m01
tcrb:htbi-m02
tcrb:htbi-m03
tcrb:htbi-m04
tcrb:htbi-m05
tcrb:htbi-m06
tcrb:htbi-m08
tcrb:htbi-m09
tcrb:htbi-m10
tcrb:htbi-m11
tcrb:htbi-m15
tcrb:htbi-m17
tumorsize:1.3
tumorsize:2
tumorsize:2.5
tumorsize:3
tumorsize:4
tumorsize:5
tumorsize:5.5
tumorsize:6
tumorsize:6.5
tumorsize:7
tumorsphere:established
tumorsphere:novel
tumour:colorectal cancer
vitamin_d_level:126
vitamin_d_level:20
vitamin_d_level:21
vitamin_d_level:24
vitamin_d_level:25
vitamin_d_level:33
vitamin_d_level:36
vitamin_d_level:40
vitamin_d_level:43
vitamin_d_level:45
vitamin_d_level:54
vitamin_d_level:60
vitamin_d_level:61
vitamin_d_level:62
vitamin_d_level:63
vitamin_d_level:66
vitamin_d_level:71
vitamin_d_level:77
vitamin_d_level:78
vitamin_d_level:79
vitamin_d_level:83
vitamin_d_level:84
vitamin_d_level:89
vitamin_d_level:91
vitamin_d_level:94
weight:44
weight:48
weight:50
weight:52
weight:54
weight:55
weight:56
weight:58
weight:59
weight:60
weight:61
weight:62
weight:63
weight:65
weight:66
weight:67
weight:68
weight:69
weight:70
weight:71
weight:72
weight:75
weight:80
weight:87
weight:normal weight
weight:obese
weight:over